Financial Recovery Following its recent emergence from Chapter 11 bankruptcy, Endo is likely focused on stabilizing and expanding its market presence. This presents an opportunity to offer financial and operational solutions that support their growth and restructuring efforts.

Innovative Developments Endo's launch of the Spatial Computing Injection Simulator indicates a significant investment in cutting-edge technology for drug development and training. Sales teams could explore partnerships or procurements related to advanced simulation and digital health solutions.

Market Expansion The sale of assets to Knight Therapeutics and ongoing product launches such as branded TV and digital advertising suggest a strategic shift towards market differentiation and expansion, especially in Canadian and niche therapeutic segments.

Technology Adoption Endo's use of diverse tech stacks like Snowflake, DocuSign, and Akamai mPulse signals their focus on data-driven decision making, digital transformation, and secure transactions, providing opportunities to offer tailored enterprise software, analytics, or cloud solutions.

Industry Competition As a mid-sized player with revenue between 100M and 250M, Endo aims to compete with larger pharmaceutical entities. Engaging with specialized suppliers of clinical, manufacturing, or regulatory compliance technologies could be a strategic move to capture their growth opportunities.